Loss of nectin‐3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor
Sign Up to like & getrecommendations! Published in 2019 at "Pathology International"
DOI: 10.1111/pin.12881
Abstract: Pancreatic neuroendocrine tumors (PanNETs) are rare, and prediction of aggressive characteristics, such as recurrence and metastasis and prognosis of PanNETs remain difficult. Nectins are cell adhesion molecules that regulate the formation of adherens and tight… read more here.
Keywords: nectin expression; tumor aggressiveness; pancreatic neuroendocrine; tumor ... See more keywords
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-1764
Abstract: Abstract Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior… read more here.
Keywords: nectin expression; enfortumab vedotin; membranous nectin; expression ... See more keywords
Abstract 4867: Effect of FGFR3 activity on Nectin-4 expression in urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4867
Abstract: Bladder cancer is a common malignancy in the U.S. and cause of significant morbidity and mortality. Combination platinum-based chemotherapy has long been the mainstay in the treatment of metastatic urothelial carcinoma (mUC); however, over the… read more here.
Keywords: nectin expression; cell; expression; urothelial carcinoma ... See more keywords
Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.463
Abstract: 463Background: Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting Nectin-4 (encoded by the PVRL4/NECTIN4 gene) approved for treatment-refractory metastatic urothelial cancer. Fac... read more here.
Keywords: heterogeneity nectin; nectin expression; enfortumab vedotin; urothelial cancer ... See more keywords